SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

SEGURA BENEDICTO, Andreu. La supuesta asociación entre la vacuna triple vírica y el autismo y el rechazo a la vacunación. Gac Sanit [online]. 2012, vol.26, n.4, pp. 366-371. ISSN 0213-9111.  http://dx.doi.org/10.1016/j.gaceta.2011.11.018.

    1. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998; 351:637-41. (RETRACTED). [ Links ]

    2. Fudenberg HH. Dialysable lymphocite extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996; 9:13-7. [ Links ]

    3. Gupta S. Immunology and immunologic treatment of autism. Proc Natl Autism Assn Chicago. 1996; 455-60. [ Links ]

    4. Miller D, Wasworth J, Diamond J, et al. Measles vaccination and neurological events. Lancet. 1997; 349:730-1. [ Links ]

    5. Wing L. Autism spectrum disorders (no evidence for or against an increase of prevalence). BMJ. 1996; 312:327-8. [ Links ]

    6. Trilla A. Vacunes: una realitat contrastada i atacada. Annals de Medicina. 2010; 93:5-7. [ Links ]

    7. Deer B. How the vaccine crises was meant to make money. BMJ. 2011; 342:136-42. [ Links ]

    8. Chen RT, Destefano F. Vaccine adverse effects: causal or coincidental?. Lancet. 1998; 351:611-2. [ Links ]

    9. Lee JW, Melgaard B, Clements CJ, et al. Autism, inflammatory bowel disease and MMR vaccine. Lancet. 1998; 351:905. [ Links ]

    10. Bignall J. UK experts convinced on safety of MMR. Lancet. 1998; 351:966. [ Links ]

    11. Horton R. A statement by the editors of the Lancet. Lancet. 2004; 363:820-1. [ Links ]

    12. Horton R. The lessons of MNR. Lancet. 2004; 363:747-8. [ Links ]

    13. General Medical Council. Fitness to practice panel hearing. 2010. (Consultado en abril de 2011.) Disponible en: http://www.gmc-uk.org/static/documents/content/Wakefield__Smith__Murch. [ Links ]

    14. Deer B. How the case against the MMR vaccination was fixed. BMJ. 2011; 342:77-82. [ Links ]

    15. Steen GR. Retractions in the scientific literature: is the incidence of research fraud increasing?. J Med Ethics. 2011; 37:249-53. [ Links ]

    16. Greenhalhg T. Why did the Lancet take so long? The retraction of the infamous MMR paper may be overdue, but it is a good thing for science. BMJ. 2010; 340:294. [ Links ]

    17. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002; 347:1335-41. [ Links ]

    18. Mello MM, Claridge BR, Studdert LLB. Academic medical center's standards for clinical-trial agreements with industry. N Engl J Med. 2005; 352:2202-10. [ Links ]

    19. Martinson BC, Anderson MS, de Vries RG. Scientists behaving badly. Nature. 2005; 435:737-8. [ Links ]

    20. Buuel lvarez JC, Gonzlez de Dios J. Los ensayos clnicos financiados por la industria tienen mayor probabilidad de encontrar resultados favorables al frmaco objeto de estudio. Evid Pediatr. 2010; 6:77. [ Links ]

    21. Burgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in clinical trials.gov. Ann Inter Med. 2010; 153:158-66. [ Links ]

    22. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006; 333:782. [ Links ]

    23. Angell M. The truth about drug companies: how they deceive us and what to do about it. New York: Random House; 2005. [ Links ]

    24. Horton R. The dawn of McScience. New York Rev Books. 2004; 51:7-9. [ Links ]

    25. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine. 2005; 2:e138. [ Links ]

    26. Godlee F. We want raw data, now. BMJ. 2009; 339:b5405. [ Links ]

    27. Wager L. Does the Wakefiekd et al. case mean we should demand public www. access to raw data?. BMJ Group blogs. 2011. (Consultado en abril de 2011.) Disponible en:http://blogs.bmj.com/bmj/2011/01/10. [ Links ]

    28. Institute of Medicine Immunization Safety Review Committee. Vaccines and autism. Washington: The National Academies Press; 2004. [ Links ]

    29. Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet. 1998; 351:1327-8. [ Links ]

    30. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit. 2004; 10:P133.9. [ Links ]

    31. Geier M, Geier D. Pediatric MMR vaccination safety. International Pediatrics. 2003; 18:203-8. [ Links ]

    32. Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS ONE. 2008; 3:e3140. [ Links ]

    33. Thompson WW, Price C, Goodson B, et al, Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007; 357:1281-92. [ Links ]

    34. Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010; 126:656-64. [ Links ]

    35. Takeuchi T, Eto K. The pathology of Minamata disease. Fukuoka: Kyushu Univ Press; 1979. 757-805. [ Links ]

    36. Offit PA. Thimerosal and vaccines a cautionary tale. N Engl J Med. 2007; 357:1278-9. [ Links ]

    37. Hutchins SS, Baughman AL, Orr M, et al. Vaccination levels associated with lack of transmission among preschool-aged population in the United States, 1989-1991. J Infect Dis. 2004; 189:S108-15. [ Links ]

    38. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ. 2005; 330:1132-5. [ Links ]

    39. Stevenson J, Murdoch G, Riley A, et al. Implementation and evaluation of a measles/rubella vaccination campaign in a campus university in the UK following an outbreak of rubella. Epidemiol Infect. 1998; 121:157-64. [ Links ]

    40. Middleton E, Baker D. Comparison of social distribution of immunization with measles, mumps, and rubella vaccine, England, 1991-2001. BMJ. 2003; 326:854. [ Links ]

    41. Wright JA, Polak C. Understanding variation in measles-mumps-rubella immunization coverage - a population-based study. E J Public Health. 2005; 16:137-42. [ Links ]

    42. Andeberger D, Chevalier A, Wadsworth J. Anatomy of a health scare: education, income and the MMR controversy in the UK. J Health Econ. 2011. [ Links ]

    43. Heathcock R, Watts C. Measles outbreaks in London, United Kingdom - a preliminary report. Euro Surveill. 2008; 13:18829. Disponible en: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18829 . [ Links ]

    44. Lpez Hernndez B, Laguna Sorinas J, Marn Rodrguez I, et al. Spotlight on measles 2010: an ongoing outbreak of measles in an unvaccinated population in Granada, Spain, October to November 2010. Euro Surveill. 2010; 15:pii=19746. Disponible en:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19746 . [ Links ]

    45. Oficina Europea de la OMS. Measles outbreaks spread across Europe: European Immunization Week offers chance to promote immunization. (Consultado en abril de 2011.) Disponible en: http://www.euro.who.int/. [ Links ]

    46. Barrabeig I, Rovira A, Muoz P, et al. MMR vaccine effectiveness in an outbreak that envolved day-care and primary schools. Vaccine. 2011; 29:8024-31. [ Links ]

    47. Bernouilli D. Essai d'une nouvelle analyse de la mortalit caus par la petite vrole et des avantages de l'innoculation pour la prvenir. Mmoires de mathmatique et de physique. Pars: Acadmie Royal des Sciences; 1760. [ Links ]

    48. Poland GA, Jacobson RM. The age-old struggle against the antivaccinationists. N Engl J Med. 2011; 364:97-9. [ Links ]

    49. Meade T. Living worse and costing more: resistance and riot in Rio de Janeiro, 1890-1917. J Lat Amer Studies. 1989; 21:241-66. [ Links ]

    50. Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in UK 1998-2005: inevitable community outrage or a failure of risk communications. Vaccine. 2006; 24:3921-8. [ Links ]

    51. Byers RK, Moll FC. Encephalopathies following prophylactic pertussis vaccine. Pediatrics. 1948; 1:437-57. [ Links ]

    52. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of antivaccine mouvements on pertussis control: the untold story. Lancet. 1998; 351:356-61. [ Links ]

    53. Baker J. The pertussis vaccine controversy in Great Britain, 1974-86. Vaccine. 2003; 21:4003-10. [ Links ]

    54. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Nature. 2010; 330:982-5. [ Links ]

    55. Smith A, Yarwood J, Salisbury DM. Tracking mothers' attitudes to MMR immunization 1996-2006. Vaccine. 2007; 25:3996-4002. [ Links ]

    56. Casiday R, Cresswell T, Wilson D, et al. A survey of UK parental attitudes to the MMR vaccine and trust in medical authority. Vaccine. 2006; 24:177-84. [ Links ]

    57. Morat ML. Grupo de prevencin de enfermedades infecciosas del PAPPS/SEMFyC. Comunicacin personal. Disponible en: https://saluda.salud.madrid.org/DG de Atencion Primaria/Bcalendario_vacinfantil/Calendario bolsillo 2009.pdf. [ Links ]

    58. Colgrove J, Abiola S, Mello MM. HPV vaccination mandates-lawmaking amid political and scientific controversy. N Engl J Med. 2010; 363:785-91. [ Links ]

    59. Lexchin J, Arya N, Singh S. Gardasil® - The new HPV vaccine: the right product, the right time? A commentary. Health Care Policy. 2010; 5:26-36. [ Links ]

    60. Segura A. Aspectes tics de la vacunaci contra el virus del papilloma hum Biotica & Debat. 2009; 15:11-4. [ Links ]

    61. Wynis MK. Public health, public trust and lobbying. Am J Bioethics. 2007; 7:4-7. [ Links ]

    62. Nabel GJ, Wei C-J, Ledgerwood JE. Vaccinate for the next H2N2 pandemic now. Nature. 2011; 471:157-8. [ Links ]

    63. Segura A. Qu se puede aprender de la gestin de la gripe pandmica?. Gac Sanit. 2010; 24:269-71. [ Links ]

    64. Gervas J. Vacuna contra la gripe 2011-2012, una vacuna terminator. Ms razones para el "no" razonable de profesionales y pacientes (ao 2011). Disponible en: http://www.equipocesca.org/. [ Links ]

    65. Puig J, Aldaz P, lvarez MJ, et al. Grupo de Prevencin de Enfermedades Infecciosas del PAPPS. Debemos recomendar la vacuna de la gripe a nuestros pacientes? AMF SEMFyC (ao 2011). Disponible en: http://rafalafena.files.wordpress.com/2011/10/editorial-gripe1-vancouver-1definitiva.pdf. [ Links ]

    66. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy an effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet. 2011. DOI: 10.1016/S1473-3099(11)70295-X. Disponible en:http://www.thelancet.com/infection. [ Links ]

    67. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ. 1981; 282:1847-51. [ Links ]

    68. Meneu R. Autonoma, beneficencia y maleficencia en los programas de prevencin. A propsito de la informacin sobre el cribado de cncer de mama. Barcelona: Fundacin Grfols; 2011. p. 51-2. [ Links ]

    69. Nigenda-Lpez G, Orozco E, Leyva R. Motivos de no vacunacin: un anlisis crtico de la literatura internacional. Rev Sade Pblica. 1997; 31:313-21. [ Links ]

    70. Gust DA, Darling N, Kennedy A, et al. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics. 2008; 122:728-825. [ Links ]

    71. Lam PP, Chambers LW, MacDougall DM, et al. Seasonal influenza vaccination campaigns for health care personnel: systematic review. CMAJ. 2010; 182:E542-8. [ Links ]

    72. Bedford HE, Elliman DA. MMR vaccine and autism (health professionals must enter the public arena if future debacles are to be prevented). BMJ. 2010; 340:271-2. [ Links ]